The UK respiratory device market was valued at around $1.4 billion in 2018 and is estimated to grow at a CAGR of around 6.2% during the forecast period. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors that augmenting the growth of respiratory device market in the country. The increasing demand from chronic obstructive pulmonary disease (COPD), Sleep Apnea and asthma patients in the country is further favoring the growth of the market. 

The UK respiratory device market is segmented on the basis of product and end-user. The respiratory product segment is further sub-segmented into therapeutic devices, diagnosis and monitoring devices, and consumables and accessories. The therapeutic devices segment is estimated to dominate the market and is also anticipated to grow at the fastest growth rate over the forecast period. The high cost of therapeutics device and significant demand for continuous positive airway pressure (CPAP) devices and masks, ventilator, oxygen concentrator, and oxygen hoods contribute majorly to the segmental growth of the market for therapeutic devices. Based on end-user, the market is analyzed into hospitals and clinics, and home care. 

Some of the major UK based companies working in the field of respiratory device market are AstraZeneca, Anaxys, Avita Medical, Bioxydyn, Circassia, Edixomed Ltd., Verona Pharma PLC., VirionHealth Ltd., Oxagen Ltd., Oxehealth, Peptinnovate, GM Instruments, PneumaCare Ltd. SIME Diagnostics Limited, Synairgen PLC. These companies are involved in various market activities such as product development, collaboration product launch and others in the country. UK based company, Circassia launched Niox Vero nasal mode in Europe for screening the primary ciliary dyskinesia in September 2017. The company got into collaboration with AstraZeneca in March 2017 and acquired Prosonix, Ltd. June in 2015. 

Edixomed, Ltd. is a clinical-stage biotechnology organization company located in London. The company has various respiratory phase products including treatments for ventilator-associated pneumonia and cystic fibrosis, the ventilator acquired pneumonia treatment medicine is in phase 1 of clinical trial whereas treatment for cystic fibrosis is in pre-clinical stage. Another clinical-stage biopharmaceutical company in UK is Verona Pharma PLC. The company offers RPL554 for the cure of respiratory diseases. In March 2017, the company entered into a global services agreement with QuintilesIMS, in order to facilitate its global clinical trial-related activities for the development of its product candidate RPL554 for the treatment of COPD and cystic fibrosis and for future commercialization initiatives. 

 Research Methodology

The market study of the UK respiratory device market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog

The report is intended for respiratory device manufacturers, contract research organizations (CROs), the healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. UK Respiratory Device Market Research and Analysis by Product
2. UK Respiratory Device Market Research and Analysis by End-User

The Report covers:

• Comprehensive research methodology of the UK respiratory device market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK respiratory device market.
• Insights about market determinants which are stimulating the UK respiratory device market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.